Neogene Therapeutics is at the forefront of developing next-generation engineered T cell receptor (TCR) therapies specifically targeting neoantigens in solid tumors. Their innovative approach focuses on harnessing tumor-specific TCRs that recognize mutations unique to individual patients' tumors, as well as shared neoantigens arising from common driver mutations like KRAS and TP53. By utilizing a proprietary TCR identification and selection platform, Neogene aims to create both fully individualized T cell therapies and shared neoantigen-targeted therapies. This dual strategy is designed to address the significant unmet need for effective treatments in advanced solid cancers, which have historically been challenging to treat due to limited safe drug targets.

The company’s pipeline includes promising candidates such as NT-175 and NT-112, which are engineered to target specific mutations in TP53 and KRAS, respectively. These therapies are designed to enhance T cell activity through genetic modifications, thereby improving the therapeutic response. Neogene's commitment to advancing cancer treatment is further exemplified by their focus on multi-specific T cell therapies, which aim to target multiple neoantigens simultaneously, potentially reducing the risk of therapy-induced resistance. Through ongoing clinical trials and a robust research framework, Neogene Therapeutics is poised to transform the landscape of solid cancer treatment with its cutting-edge TCR technologies.

Netherlands

Neogene Therapeutics is a global, clinical-stage biotechnology company pioneering the discovery, development, and manufacturing of next-generation engineered T cell receptor (TCR) therapies targeting a broad spectrum of solid cancers. With offices in Santa Monica, CA and Amsterdam, the Netherlands, Neogene is aiming to change the paradigm of treatment for solid cancers. Neogene is a member of the AstraZeneca Group.

Neogene Therapeutics

Company Details